Berbice Capital Management LLC Makes New Investment in Astera Labs, Inc. (NASDAQ:ALAB)

Berbice Capital Management LLC bought a new stake in Astera Labs, Inc. (NASDAQ:ALAB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 650 shares of the company’s stock, valued at approximately $86,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Wesbanco Bank Inc. purchased a new stake in shares of Astera Labs in the 4th quarter valued at about $331,000. Dakota Wealth Management lifted its holdings in shares of Astera Labs by 2.5% in the 4th quarter. Dakota Wealth Management now owns 43,110 shares of the company’s stock valued at $5,710,000 after purchasing an additional 1,049 shares during the last quarter. Trueblood Wealth Management LLC purchased a new stake in shares of Astera Labs in the 4th quarter valued at about $331,000. Mandatum Life Insurance Co Ltd purchased a new stake in shares of Astera Labs in the 4th quarter valued at about $462,000. Finally, Oak Ridge Investments LLC purchased a new stake in shares of Astera Labs in the 4th quarter valued at about $284,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 16,000 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $117.84, for a total transaction of $1,885,440.00. Following the sale, the chief financial officer now owns 1,412,888 shares in the company, valued at approximately $166,494,721.92. This represents a 1.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stefan A. Dyckerhoff sold 50,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $89.70, for a total value of $4,485,000.00. Following the sale, the director now owns 129,617 shares in the company, valued at approximately $11,626,644.90. This trade represents a 27.84 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,690,452 shares of company stock worth $167,581,256.

Analyst Upgrades and Downgrades

ALAB has been the subject of several research reports. Northland Capmk downgraded Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 2nd. JPMorgan Chase & Co. upped their price objective on Astera Labs from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Morgan Stanley downgraded Astera Labs from an “overweight” rating to an “equal weight” rating and set a $142.00 price objective for the company. in a research note on Tuesday. Northland Securities downgraded Astera Labs from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $100.00 to $120.00 in a research note on Thursday, January 2nd. Finally, Stifel Nicolaus upped their price objective on Astera Labs from $100.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Astera Labs presently has an average rating of “Moderate Buy” and a consensus target price of $109.75.

Astera Labs Stock Performance

ALAB opened at $122.37 on Friday. The stock’s 50 day simple moving average is $121.72 and its 200 day simple moving average is $78.06. Astera Labs, Inc. has a 1-year low of $36.22 and a 1-year high of $147.39.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings results on Monday, November 4th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.06. The business had revenue of $113.10 million for the quarter, compared to analysts’ expectations of $97.50 million. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The company’s quarterly revenue was up 47.1% on a year-over-year basis. On average, equities analysts expect that Astera Labs, Inc. will post -0.45 EPS for the current year.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.